Probes Watch Your Heart Skip a Beat
GARY BOAS, NEWS EDITOR, GARY.BOAS@PHOTONICS.COMFluorescence enables optical mapping of cardiac arrhythmias
While many cases of cardiac arrhythmia are harmless, others can lead to loss of heart function, breathing and consciousness, which can be dangerous and even fatal. And arrhythmias – that is, irregular or abnormal heartbeats – are not uncommon. Atrial fibrillation, one of the most common arrhythmias, affects 2.7 million people in the US alone, according to the American Heart Association.
Better understanding of how cardiac arrhythmias work will of course help to advance their prevention and treatment. Traditionally, surface electrodes have been used to this end; after all, arrhythmias are the result of a malfunction of the electrical impulses in the heart. But this approach is limited, suffering from low spatial resolution, low depth of field and far-field effects, for example.
Optical mapping studies are providing important insights into the mechanistic origins of cardiac arrhythmias such as atrial fibrillation.
Optical mapping with fluorescent probes – using voltage- and calcium-sensitive dyes, for example – offers a means to study the electrical activity of the heart with much higher spatial resolution than is possible with conventional electrode mapping, and furthermore contributes to better understanding of the coupling between excitation and contraction in the heart. Thus it can provide an important tool for exploring the underpinnings of arrhythmias.
“The ultimate utility of optical mapping is to provide mechanistic insight into how arrhythmias occur in disease settings,” said Todd Herron, an investigator in the University of Michigan Center for Arrhythmia Research and lead author of a recent Circulation Research
review of the technique (doi: 10.1161/circresaha.111.247494
). “By knowing how electrical impulses are propagating in diseased hearts, we hope to provide information on how to prevent or treat fatal cardiac arrhythmias.”
Optical mapping of the heart has grown in prominence in recent years, in large part thanks to advances in the technology. “Ten years ago, to do this type of imaging, you had to be an engineer building your own system,” said Igor Efimov, a researcher at Washington University in St. Louis who has worked to develop the technique since its early days. Today, cardiologists, physiologists and any number of other nonengineers can now also benefit from use of the approach.
Still, challenges remain in optical mapping studies. One of the most significant is how to account for motion artifacts – namely, for the beating of the heart. Researchers have developed a variety of means to do so. Perhaps the most common of these is using blebbistatin, a recently discovered contraction inhibitor.
Narine Sarvazyan and her colleagues at George Washington University have described methodological issues that should be taken into account in optical mapping studies using blebbistatin. For example, perfusion with blebbistatin could result in accumulation of precipitate in the vasculature, which could in turn lead to misinterpretation of the data. Shown here is an extreme case of blebbistatin precipitation in rat heart under white light (left) vs. ultraviolet illumination (right). Courtesy of Narine Sarvazyan.
Blebbistatin is a reverse inhibitor of myosin II that lowers the myosin II affinity to actin, said Luther Swift, a researcher in Narine Sarvazyan’s group at George Washington University Medical Center in Washington and lead author of a recently published paper describing the agent’s properties. This means that it “keeps the cells from actually contracting, even though the action potentials continue.”
The contraction inhibitor is quickly becoming the “compound of choice” in reducing motion artifacts during optical mapping studies, but open questions remain with respect to its use.
“The use of blebbistatin has been shown to not affect cardiac electrical activity, but this is somewhat controversial,” Herron said. “Furthermore, inhibition of contraction may have impact on the conclusions that can be drawn from optical mapping,” because the heart is an organ in constant motion and its contractile activity likely produces metabolites and other modifications that contribute to overall cardiac function.
Blebbistatin does not interfere with calcium cycling or voltage dynamics, but investigators need to keep in mind that cells expend energy on the act of contraction, Sarvazyan explained. So when contraction is inhibited or does not occur, the heart uses less energy. In studies of heart ischemia, for example, the rate of the rise in NADH – an index of ischemia – is about five times lower in the blebbistatin-treated heart than it would be otherwise.
“People who study ischemia need to be aware that there’s a marked effect of blebbistatin on cardiac metabolism,” she said.
Inhibiting contracting isn’t the only way to address motion artifacts in optical mapping of the heart. Sarvazyan points to a study by her collaborators Huda Asfour and Matthew Kay, recently published in IEEE Transactions on Biomedical Engineering
. The study describes a novel wavelet-based algorithm that allows information extraction on both electromechanical activity and motion from fluorescence imaging of transmembrane voltage-sensitive dyes.
Huda Asfour of the Kay group, together with colleagues at George Washington University, has recently described a novel postacquisition approach that allows one to extract information about both the motion and the action potentials from optical mapping of beating hearts loaded with voltage-sensitive dyes. The approach relies on different approximation coefficients from wavelet decomposition of optical signals. Courtesy of Huda Asfour/The Kay group.
Efimov and colleagues are developing another approach: combining fluorescence imaging with voltage- or calcium-sensitive dyes with a technique called structured light imaging. A mature technology used for precision shape measurement in industrial production control, as well as for realistic human performance capture in a range of entertainment applications, structured light imaging offers a means to capture changes in three-dimensional shape with high spatial and temporal resolution.
The researchers have been adapting the technique for use in the heart. “Structured light imaging used in industry or entertainment is too slow for cardiac applications,” Efimov said. “We need to improve the frame rate to 1000 frames per second using developments in [digital light processing] technology and fast imaging.”
The Efimov group has done extensive work in the area of optical mapping. At left, an anterior view of a mouse heart [LA = left atrium, RA = right atrium, RV = right ventricle, LV = left ventricle, ECG = electrocardiogram]; (center) two representative optical signals using a calcium-sensitive dye (Rhod2-AM) and a voltage-sensitive dye (RH237), [Vm = transmembrane potential]; and an activation map of the time course of electrical propagation across the mouse heart. Each isocolor represents a different activation time for that particular region of tissue. Blue represents earliest activation, and red represents latest. Courtesy of Di Lang.
Working with Song Zhang at Iowa State University, Efimov and colleagues have already achieved a rate of 667 frames per second and have reported applying the technique to capture the beating of a rabbit heart – using it to image and describe cardiac mechanics such as strain, curvature and displacement in three dimensions and, in turn, to digitally correct for motion in optical mapping studies on a pixel-by-pixel basis. The researchers hope to reach the goal of 1000 frames per second within the next year.
The structured light imaging system they used achieved frame rates of up to 667 frames per second with X,Y resolution of 87 µm and Z resolution of 10 µm. Also, a robust, nonrigid surface-matching algorithm enabled tracking of dense surface motion across 3-D surfaces over time.
Here, a schematic of a structured light imaging system used by the Efimov group and collaborators at other institutions to measure epicardial deformation in a beating rabbit heart. A digital light processing projector sequentially projects onto an object 10 binary fringe patterns, which are captured by a CMOS camera and used to produce 3-D images of the object with high spatial and temporal resolution.
Of course, identifying and accounting for motion artifacts is not the only challenge in optical mapping studies. Such studies are complex, and investigators must be aware of a host of other factors – including, for example, the possible cytotoxicity of the fluorescent probes used in the studies.
Ongoing research is helping in addressing the latter concern. A new generation of less phototoxic voltage-sensitive dyes is being developed, Herron said. Fluorescent probes that are excited by infrared light are beginning to appear, “thus eliminating the use of ultraviolet illumination that can damage biological preparations.”
One of the most important recent developments in cardiac imaging is the advancement of multiparametric imaging, which is extending optical mapping beyond the measurement of action potential and calcium waves. An example is combining mitochondrial voltage sensors with calcium measurements to gain new insight into how mitochondrial electrophysiological function affects whole cells and cardiac tissue. Measurement of intracellular pH, nuclear calcium cycling and activity of reactive oxidative species could also be accessible using fluorescent probes for these parameters.
The approach is now used by numerous investigators to study excitation-contraction coupling in normal and diseased heart, Efimov said. “More recently, several laboratories have advanced imaging of additional parameters and showed an exciting possibility to image multiple parameters simultaneously with voltage and calcium, including marker of ischemia NADH, and marker of metabolic state inner membrane potential of mitochondria.”